When: Q3 2026 earnings shows operating margin ≥15% AND EBITDA margin ≥18% AND gross margin ≥34.5%

Then: Confirm COGS-level stabilization; gross margin test is decisive per 8/25 reflection

When: Tier-1 sell-side coverage broadens beyond Morgan Stanley (Goldman, JPM, or BAC upgrade)

Then: Confirm institutional sponsorship beyond single-bank upgrade; single-bank upgrade is chase signal, not structural re-rating

Sell now at $164; eliminate 75-100% of position rather than waiting for resistance; size residual to quarter-percent of book with hard stop at $156

• ATR of $10.45 means daily range exceeds 6%; waiting for $170-$175 trim zone adds unnecessary volatility risk
• Current plan leaves 1% of book in highest-risk name in peer set; standard aerospace allocation is 4%, making residual 1% still too large
• Net debt of $14.8 billion against $3.5 billion in EBITDA creates leverage concern with rates rising
• Interest coverage of 4.4x will compress if company must refinance $15.8 billion note stack at higher rates
• Polymarket pricing shows 1% Fed cut probability by September and 12% by December—headwind still building for long-duration industrials
• 18x forward multiple does not price in refinancing shock risk
• Stock sitting 20% below declining 50 SMA; still in lower third of Bollinger Band envelope
• Distribution pattern at $170 has not broken despite two prior rejections
• Consensus earnings recovery gets compressed further if Fed stays hawkish through year-end
• Quarter-percent residual stub maintains optionality if recovery materializes without meaningfully damaging book

→ vs aggressive: Plan calls for trimming 50% into $170-$175 zone, which is where aggressive analyst himself said every rally gets sold; waiting for resistance where supply is heaviest is not trading with the trend

→ vs aggressive: 1% residual in a stock with negative book equity, $14.8 billion net debt, 1,000 basis points of EBITDA margin compression, and $10.45 ATR is the worst of both worlds—it doesn't generate meaningful return if right about recovery but bleeds the book if right about impairment

→ vs neutral: Holding is not a neutral action; it is a directional bet that current price is sustainable and downside is bounded, neither of which holds with stock 20% below declining 50 SMA and 4 dollars above 52-week low

→ vs neutral: Waiting for confirmation above $175 or below $156 means stock can move 10 dollars in either direction on any given session—riding a chop saw hoping the blade stops in a convenient place

Trim 60-70% at current prices around 164; maintain residual of 30-40% of original position

• The direction is correct but execution is flawed on both sides - aggressive analyst is too directional in waiting for 170 breakout that price action suggests won't come, while conservative analyst is too bearish by selling everything at a price that already reflects the bearish thesis
• Business fundamentals are real: 5-7% revenue growth, mid-thirties gross margins, solid normalized cash flow; negative book value is spin-off artifact not operational distress
• Q2 SG&A spike likely contains one-time spin-off costs that will normalize over 4-6 quarters; cost base is structurally higher but not catastrophically so
• Waiting for 170 requires breaking through heavy supply at a level the aggressive analyst himself identified as a ceiling; estimated 40% probability of reaching that level given distribution pattern
• At 164, fair value is estimated between conservative's 135-140 and bullish implied 200, placing current price closer to middle of range than bearish extreme
• Stop should be tightened to 156 (crash low) rather than 150; 150 is too forgiving given established support level at 156
• Re-evaluate residual at Q3 earnings: if standalone costs normalize faster than expected and guidance improves, re-engage; if structural impairment thesis reasserts, exit at stop

→ vs aggressive: Calling the MACD histogram flip a 'bear trap' before it actually traps the bears is a thesis, not a confirmed signal; waiting for 170 requires breaking through heavy supply at a level the aggressive analyst himself identified as a ceiling - probability math doesn't work in his favor at estimated 40%

→ vs conservative: Selling everything at 164 when fair value is estimated at 135-140 is a directional bet dressed up as risk management; a quarter-percent residual stub is too small to meaningfully participate in recovery but too large to genuinely represent hedging against a thesis the analyst doesn't believe in - trying to have it both ways without either side working